<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41964">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02036424</url>
  </required_header>
  <id_info>
    <org_study_id>OA 003</org_study_id>
    <nct_id>NCT02036424</nct_id>
  </id_info>
  <brief_title>A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema</brief_title>
  <official_title>A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Raj K. Maturi, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maturi, Raj K., M.D., P.C.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if there is visual benefit with Ozurdex treatment every three months compared
      to monthly anti-VEGF alone, in subjects with persistent diabetic macular edema.  We
      hypothesize more frequent administration of Ozurdex in patients that have persistent
      diabetic macular edema will result in a more rapid and sustained improvement of visual
      acuity and/or OCT compared to the use of anti-VEGF alone.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean visual acuity change</measure>
    <time_frame>baseline to month 7</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.25 mg intravitreal injection given monthly during a 6 month period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ozurdex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone intravitreal implant, 0.7 mg given every 3 months over 6 month period with a maximum of 3 injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ozurdex</intervention_name>
    <arm_group_label>Ozurdex</arm_group_label>
    <other_name>Dexamethasone Intravitreal Implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male of female age 18 years or older

          2. Type 1 or Type 2 diabetes

          3. BCVA score of &gt;24 and &lt;78 letters

          4. History of at least 3 anti-VEGF intravitreal injections over the past 5 months

          5. Presence of macular edema defined as central subfield thickness of &gt;340 microns on
             Cirrus OCT

        Exclusion Criteria:

          1. Anti-VEGF intravitreal treatment in the last 4 weeks

          2. Intravitreal steroid treatment in the last 8 weeks or Ozurdex in the last 4 months

          3. PRP or focal laser in the last 4 months

          4. Active iris neovascularization

          5. Any ocular condition in the study eye that, in the opinion of the investigator, is
             severe enough to compromise the study result

          6. Uncontrolled systemic disease

          7. Known history of IOP elevation in response to corticosteroid treatment, that is not
             controlled on 2 glaucoma medications

          8. Current enrollment in an investigational drug study or participation in such a study
             within 30 days prior to the baseline visit

          9. Female patients who are pregnant, nursing or planning a pregnancy or who are of
             childbearing potential and not using a reliable means of contraception

         10. Any condition or reason (including inability to read ETDRS chart or language barrier)
             that precludes the patient's ability to comply with study requirements including
             completion of the study

         11. Patients with active or suspected ocular or periocular infections including most
             viral diseases of the cornea and conjunctiva, including active epithelial herpes
             simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial
             infections, and fungal diseases.

         12. Aphakia or pseudophakia with anterior chamber intraocular lens

         13. Hypersensitivity to any components of Ozurdex or Avastin
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Raj K Maturi, MD</last_name>
    <phone>317-817-1414</phone>
    <email>rmaturi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Raj K Maturi MD PC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Raj K Maturi, MD</last_name>
      <phone>317-817-1414</phone>
      <email>rmaturi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Raj K Maturi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>January 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Maturi, Raj K., M.D., P.C.</investigator_affiliation>
    <investigator_full_name>Raj K. Maturi, MD</investigator_full_name>
    <investigator_title>Raj K. Maturi MD, PI</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
